We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Imatinib Mesylate for Targeting the Platelet-derived Growth Factor ß Receptor in Combination With Fluorouracil and Leucovorin in Patients With Refractory Pancreatic, Bile Duct, Colorectal, or Gastric Cancer--A Dose-escalation Phase I Trial.
- Authors
Al-Batran, Salah-Eddin; Atmaca, Akin; Schleyer, Eberhard; Pauligk, Claudia; Hosius, Christian; Ehninger, Gerhard; Jäger, Elke
- Abstract
The article presents a study which examined the dose-limiting toxicity (DLT) and maximum tolerated dose (MTD) of imatinib in combination with fluorouracil and leucovorin in patients with chemotherapy-refractory gastrointestinal cancer. The authors used a 3-patient cohor dose-escalating study design, and patients were administered with the drug combination. The study found that DLTs were severe neutropenia, central fluid retention and severe nausea in one patient each, resulting in an MTD for imatinib of 600 milligrams per day.
- Subjects
GASTROINTESTINAL cancer; FLUOROURACIL; ANTINEOPLASTIC agents; IMATINIB; FOLINIC acid; CANCER treatment
- Publication
Cancer (0008543X), 2007, Vol 109, Issue 9, p1897
- ISSN
0008-543X
- Publication type
Article
- DOI
10.1002/cncr.22622